WCM Investment Management LLC Acquires 867,673 Shares of Illumina, Inc. (NASDAQ:ILMN)

WCM Investment Management LLC raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 26.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 4,129,855 shares of the life sciences company’s stock after buying an additional 867,673 shares during the period. WCM Investment Management LLC’s holdings in Illumina were worth $551,625,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Versant Capital Management Inc grew its position in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares during the last quarter. Golden State Wealth Management LLC bought a new position in shares of Illumina during the 4th quarter worth $32,000. TD Private Client Wealth LLC grew its position in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after buying an additional 141 shares in the last quarter. Private Trust Co. NA grew its position in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after buying an additional 212 shares in the last quarter. Finally, Focused Wealth Management Inc bought a new position in shares of Illumina during the 3rd quarter worth $63,000. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 9.6 %

Illumina stock opened at $111.06 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66. The stock has a 50-day moving average price of $136.70 and a 200 day moving average price of $135.29.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. Research analysts predict that Illumina, Inc. will post 4.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ILMN. Leerink Partners increased their price target on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Citigroup cut Illumina from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. JPMorgan Chase & Co. upped their price objective on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. TD Cowen cut Illumina from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $177.00 to $140.00 in a research note on Friday. Finally, UBS Group upped their price objective on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Nine research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Illumina currently has a consensus rating of “Moderate Buy” and an average target price of $161.40.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.